AthleticsRuti Aga and the six-year ban: it wasn't the drug, it was the forged prescription that ended a career

Ruti Aga and the six-year ban: it wasn't the drug, it was the forged prescription that ended a career

**कोर उत्तर**: इथियोपियाई मैराथन धावक रूटी अगा पर AIU ने छह साल का प्रतिबंध लगाया — दो साल मेथिलप्रेडनिसोलोन (WADA वर्ग S9 ग्लूकोकोर्टिकॉइड) की उपस्थिति के लिए और चार साल नकली प्रिस्क्रिप्शन व भ्रामक बयान के लिए। प्रतिबंध 10 सितंबर से प्रभावी। **मुख्य तथ्य**: - मार्च में चीन की हाफ मैराथन जीतने के बाद लिया गया इन-कॉम्पिटिशन नमूना पॉज़िटिव पाया गया। - मेथिलप्रेडनिसोलोन ग्लूकोकोर्टिकॉइड है, एनाबॉलिक स्टेरॉयड नहीं; केवल इन-कॉम्पिटिशन प्रतिबंधित। - पर्ची लिखने वाला परिवार का सदस्य था, जिसका कोई मेडिकल रजिस्ट्रेशन नहीं था। - पर्ची पर अंकित क्लिनिक का अस्तित्व ही नहीं था; क्लिनिक ने दस्तावेज़ से इनकार किया। - अगा 2019 टोक्यो मैराथन विजेता हैं; बर्लिन 2018 में 2:18:34 का सर्वश्रेष्ठ दर्ज है। **स्रोत**: Athletics Integrity Unit (AIU) का आधिकारिक बयान; बयान जारी होने की तारीख़ स्रोत में सापेक्ष रूप में दी गई है। सज़ा की प्रारंभ तिथि 10 सितंबर है। **संबंधित प्रश्नोत्तर**: प्रश्न: छह साल की सज़ा किन दो हिस्सों से बनी है? उत्तर: दो साल उपस्थिति उल्लंघन के लिए और चार साल छेड़छाड़ (नकली प्रिस्क्रिप्शन) के लिए, दोनों 10 सितंबर से गिने जाएँगे। प्रश्न: क्या मेथिलप्रेडनिसोलोन प्रतियोगिता से बाहर वैध है? उत्तर: हाँ, WADA सूची के वर्ग S9 के तहत यह केवल इन-कॉम्पिटिशन प्रतिबंधित है, इसलिए प्रतियोगिता से बाहर लिया गया चिकित्सीय इंजेक्शन वैध रहता है। प्रश्न: क्या उनका 2019 टोक्यो खिताब रद्द होगा? उत्तर: AIU बयान उल्लंघन की सीमा नहीं बताता; उल्लंघन मार्च की दौड़ से जुड़ा है, इसलिए पहले के परिणाम अपने आप रद्द नहीं होते।

I watched the last kilometre of the 2026 Tokyo Marathon on a laptop in a London university common room, with thirty-two other people, and the watch-along chat that day stuck on a question that had nothing to do with splits. Someone asked who these Ethiopian women actually run for — whose road, whose appearance fee, whose doctor. I deflected it at the time, because Ruti Aga was crossing the line and my job was the clock. Six years later the same name surfaced on another list, and that list had no splits on it.

Ruti Aga and the six-year ban: it wasn't the drug, it was the forged prescription that ended a career

On Thursday the Athletics Integrity Unit (AIU) issued its statement: a six-year ban for Aga. An in-competition sample taken after she won a half marathon in China in March returned methylprednisolone. Two years for the presence violation, four for the document she produced — a prescription written by a family member with no medical registration, for a clinic that did not exist. The mixed zone nobody wanted was always the place where the truth walked past; this time it arrived in a press release, standing still.

Context: the prescription that never reached a clinic

According to the AIU statement, Aga cited a knee injury and said the substance was given as treatment. The clinic named on the prescription denied that any such clinic existed. The man who wrote it said he had used "an old prescription pad from a former workplace" — three separate verification failures: the clinic's existence, the writer's credentials, the document's authenticity. She had been provisionally suspended since 10 September, and the ban is counted from the same date.

A technical correction is necessary here, because most coverage has repeated one error. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, WADA Prohibited List class S9, and under the current List it is prohibited in-competition only — by injection, oral or rectal route. A therapeutic injection given out of competition is entirely lawful; it becomes a violation only if residues are present in an in-competition sample. Misread that sentence and the whole case is misread.

Aga's record has to be read separately from that debate. She won Tokyo in 2026, holds a personal best of 2:18:34 from Berlin 2026, and finished second at three World Marathon Majors. That is the record of a runner who was genuinely elite on the roads, not one invited for form. Now, at 32, with six years attached to her name, she is off them.

Core: the arithmetic of six years, and a defence destroyed by hand

The sanction architecture is standard, which makes it easy to read and uncomfortable to accept. Two years for presence — the default for a Specified Substance where intent is not established. Four years for tampering — the Code's flat sanction, not an enhancement. Together they make six. What is invisible matters more: had the panel found no significant fault, the presence period could have been reduced. The six tells us no mitigation was accepted at all.

There is a near-paradox. A forged prescription is itself circumstantial evidence of concealment intent, yet it did not escalate the presence charge — because the two charges are separate and proven separately. The paperwork case is a different argument from the drug case, and that is the real architecture here. Counting the ban from 10 September is not a discount; provisional suspension time is credited, and the athlete gains nothing in real terms.

The hinge is pharmacology. In road racing the in-competition testing window opens at 23:59 the day before the race. An injection given three or four days earlier will be caught in the sample, however legitimate the treatment. The reverse is equally true: out of competition, the same injection is lawful, provided route, timing and records are handled properly.

So a defence existed, and it rested on paper. A documented treatment history, an injection date, a route, a registered physician — those could have supported an argument that the violation was not intentional. She replaced that defence with a forged document, and in that instant the defence was gone. This was not a filing error. It is the signature of an athlete operating without a credentialed team physician.

Three verification failures at once is itself a message. Had the clinic existed, had the doctor been registered, had the pad genuinely come from that practice, this would probably not be a six-year story. All three broke together because the structure around this athlete was not a medical system; it was a personal arrangement.

The economic tier she raced on is now the most scrutinised tier there is. After 2026, Aga's pattern was familiar: few races, selected Majors, and Asian label races in between where appearance fees are good and fields are thinner. The March half marathon in China belongs to that tier. It has been the most reliable income stream for East African marathoners, and it is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races.

One thing the statement leaves unsaid: what happens to that March result and its prize money. Standard AIU practice disqualifies the competition at which the sample was collected — the win, the cheque, the ranking points that followed. That is the part press releases quietly omit, and the part a reader has to assemble. Waiting in corridors taught me this: the story walks past at eye level, not from a podium.

In career terms the outcome is severe. Six years at 32 means returning at 38. Ethiopia's women's marathon depth is such that a 2:18 performer is not automatically selectable — and a 38-year-old returning with a doping record is effectively unselectable. The ban swallows the entire 2028 Olympic cycle.

And yet the record does not disappear. The violation is anchored to that March race; absent a finding of earlier use, the 2026 Tokyo title and the three Major runner-up finishes are not automatically annulled. The statement does not state the scope of disqualification, so two things will sit in the same list: an excellent marathon career, and a six-year ban. Holding both is necessary for Indian readers too, because we make the same mistake at home — we remember either all the glory or all the shame.

Watching through a screen taught me which details survive the distance and which ones don't. The finish line survives. The system that got her there does not — whose doctor, whose TUE, whose money.

Contrarian: the six years are not about the drug

Here is what mainstream coverage has almost entirely missed. Glucocorticoids have no established endurance benefit — they treat pain and inflammation, they are not performance tools. So what are six years for? They are for the paperwork. Had Aga kept honest records of a knee treatment and explained route and timing, the worst case was a two-year argument; the best case was no case at all.

This is simultaneously evidence of rigour and of inconsistency, and both need reading. On one side, the system is showing that its frontier has moved from detection to document verification. On the other, that verification burden falls on entourages with the thinnest medical infrastructure — while the races writing the appearance-fee cheques face nothing. Why does accountability terminate at the athlete and not at the promoter?

Second, vocabulary. Calling this a "steroid" turns a route-and-timing case into a morality tale and erases the single fact that might have saved her. And in AIU cases where tampering is built from interview statements, language and translation conditions are never neutral. That is a question, not an accusation — and the statement contains no athlete's-side account and no mention of her agency. That silence should be read too.

Takeaway: the question is the doctor

More cases from the same clusters will arrive in the coming months, because the informal medical networks serving one training group serve many. The next time a 2:18 woman stands on a start line with a sore knee, the question will not be what she took. It will be who her doctor was, who kept her records, and who taught her that telling the truth is safer than a prescription pad.

संबंधित खिलाड़ी